Combined lipid goal attainment in patients with type 2 diabetes and dyslipidemia: A head-to-head comparative trial of statins. Issue 8 (20th June 2022)

• Record Type: Journal Article
• Authors: Wu, Tsung-Hui; Lee, I-Te; Ho, Low-Tone; Sheu, Wayne H.-H.; Hwu, Chii-Min
• Is Part Of: Journal of the Chinese Medical Association. Volume 85:Issue 8(2022)
• Page Start: 831
• Page End: 838
• Publication Date: 2022-06-20
• Subjects: Dyslipidemia -- Lipid goals -- Rosuvastatin -- Simvastatin -- Type 2 diabetes; Medicine -- Periodicals; 610.5
• DOI: 10.1097/JCMA.0000000000000765
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : Background: This study compared the efficacy of two statin treatments (simvastatin vs rosuvastatin) in achieving the combined goal of low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L and non–high-density lipoprotein cholesterol (non–HDL-C) <3.4 mmol/L in patients with type 2 diabetes and dyslipidemia. Methods: After a 5-week run-in, 89 patients with type 2 diabetes having fasting triglyceride (TG) levels of 1.7 to 5.7 mmol/L or non–HDL-C levels of 3.4 to 5.2 mmol/L were randomized to receive simvastatin 20 mg daily for 4 weeks followed by 40 mg for 8 weeks or rosuvastatin 10 mg for 4 weeks followed by 20 mg for 8 weeks. The primary end-point was the percentage of patients achieving the combined goal at week 12. Results: Although significant between-group differences were observed in changes in LDL-C and non–HDL-C levels, both study treatments were sufficiently intensive for a 40% to 55% LDL-C reduction. At the end of the study, the two groups had similar percentages of patients who achieved the combined lipid goal (84% vs 89%, p = 0.66). All patients who attained the combined lipid goal also met the apolipoprotein B (Apo-B) target of <0.9 g/L. No between-group differences were noted in changes in HDL-C and TG levels at week 12. The patients tolerated both treatments well. Conclusion: In our study, ≈85% of patients with type 2 diabetes and dyslipidemia could achieve the combined lipid goal with statin monotherapy. The two statin treatments could sufficiently control diabetic dyslipidemia (NCT00506961).